Palbociclib
爱博新(Ibrance)
The first CDK4/6 inhibitor pill, combined with hormone therapy for HR-positive breast cancer.
At a glance
China price
Verified pricing is not currently available.
NRDL (national insurance)
NRDL status pending verification.
Regulatory status
NMPA approved (2018); NRDL (2019)
What this meansSupported by a credible secondary source but not yet independently confirmed against a primary source.
SourceNo independent source on file.
NotesApproval status from public regulatory reporting.
What it treats
HR-positive/HER2-negative advanced breast cancer with endocrine therapy.
Sources & verification
No independent source is currently on file. We have not independently verified this information.
Reader discussion
Public comments about Palbociclib. Discussion is not medical advice, and a comment is not an endorsement or a verified fact. Open the full forum.